Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use

Conan MacDougall; Spencer E Harpe; J Patrick Powell; Christopher K Johnson; Michael B Edmond; Ron E Polk

doi:10.3201/eid1108.050116

Back

Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use

Journal article

Open access

Peer reviewed

Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use

Conan MacDougall, Spencer E Harpe, J Patrick Powell, Christopher K Johnson, Michael B Edmond and Ron E Polk

Emerging infectious diseases, Vol.11(8), pp.1197-1204

08/2005

DOI: 10.3201/eid1108.050116

PMCID: PMC3320507

PMID: 16102307

Files and links (1)

url

https://doi.org/10.3201/eid1108.050116View

Published (Version of record) Open Access

Abstract

Few long-term multicenter investigations have evaluated the relationships between aggregate antimicrobial drug use in hospitals and bacterial resistance. We measured fluoroquinolone use from 1999 through 2003 in a network of US hospitals. The percentages of fluoroquinolone-resistant Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA) were obtained from yearly antibiograms at each hospital. Univariate linear regression showed significant associations between a hospital's volume of fluoroquinolone use and percent resistance in most individual study years (1999-2001 for P. aeruginosa, 1999-2002 for S. aureus). When the method of generalized estimating equations was used, a population-averaged longitudinal model incorporating total fluoroquinolone use and the previous year's resistance (to account for autocorrelation) did not show a significant effect of fluoroquinolone use on percent resistance for most drug-organism combinations, except for the relationship between levofloxacin use and percent MRSA. The ecologic relationship between fluoroquinolone use and resistance is complex and requires further study.

United States

Pseudomonas aeruginosa - isolation & purification

Staphylococcal Infections - drug therapy

Staphylococcus aureus - isolation & purification

Pseudomonas Infections - drug therapy

Humans

Pseudomonas aeruginosa - growth & development

Fluoroquinolones - therapeutic use

Linear Models

Pseudomonas aeruginosa - drug effects

Pseudomonas Infections - microbiology

Cross Infection - drug therapy

Cross Infection - microbiology

Drug Resistance, Multiple, Bacterial

Retrospective Studies

Staphylococcal Infections - microbiology

Staphylococcus aureus - drug effects

Staphylococcus aureus - growth & development

Longitudinal Studies

Details

Title: Subtitle: Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use
Creators: Conan MacDougall - Virginia Commonwealth University School of Pharmacy, Richmond, Virginia 23298-0533, USA
Spencer E Harpe
J Patrick Powell
Christopher K Johnson
Michael B Edmond
Ron E Polk
Resource Type: Journal article
Publication Details: Emerging infectious diseases, Vol.11(8), pp.1197-1204
DOI: 10.3201/eid1108.050116
PMID: 16102307
PMCID: PMC3320507
NLM abbreviation: Emerg Infect Dis
ISSN: 1080-6040
eISSN: 1080-6059
Publisher: United States
Language: English
Date published: 08/2005
Academic Unit: Internal Medicine
Record Identifier: 9983905648502771

Metrics

45 Record Views

57 Times Cited - Web of Science